8V6.F SCANDINAV.CHEMOTECH CL.B
- Market cap
- EUR 3.57M
- P/E
- -
- P/B
- 310.07x
- ROE
- -5,499.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 8V6.F undervalued?
Graham numberThe Graham number of SCANDINAV.CHEMOTECH CL.B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SCANDINAV.CHEMOTECH CL.B fundamental analysis
No fundamental analysis for SCANDINAV.CHEMOTECH CL.B yet.
SCANDINAV.CHEMOTECH CL.B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SCANDINAV.CHEMOTECH CL.B
Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTech AB (publ) and changed its name to Neem's Hill AB in July 2026. The company wa…
Full company profileSCANDINAV.CHEMOTECH CL.B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SCANDINAV.CHEMOTECH CL.B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 473K | 2.82M | 6.57M | 12.3M | 12.6M |
| Gross Profit | -55.0K | 1.66M | 4.78M | 10.3M | 11.1M |
| Operating Income | -20.9M | -20.2M | -12.8M | -6.46M | -5.95M |
| EBITDA | -17.9M | -17.0M | -10.5M | -4.14M | -4.55M |
| Net Income | -22.7M | -21.1M | -13.7M | -8.06M | -7.31M |
| EPS | -1.89 | -1.13 | -0.59 | -0.32 | -0.28 |
| Balance Sheet | |||||
| Total Assets | 21.7M | 14.9M | 13.4M | 13.2M | 13.1M |
| Total Liabilities | 7.71M | 3.84M | 7.40M | 10.0M | 12.9M |
| Shareholders' Equity | 14.0M | 11.0M | 5.98M | 3.19M | 133K |
| Cash & Short-term Investments | 5.85M | 923K | 949K | 3.67M | 1.92M |
| Cash Flow | |||||
| Operating Cash Flow | -19.5M | -18.2M | -13.1M | -3.75M | -7.19M |
| Capital Expenditure | 331K | 680K | 46.0K | 437K | 0.00 |
| Free Cash Flow | -19.8M | -18.9M | -13.1M | -4.18M | -7.19M |
| Ratios | |||||
| ROE | -162.6% | -191.2% | -229.4% | -252.9% | -5,499.7% |
| ROA | -104.8% | -141.8% | -102.5% | -61.0% | -56.0% |
| Net Profit Margin | -4,808.9% | -747.4% | -208.9% | -65.6% | -58.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SCANDINAV.CHEMOTECH CL.B dividends
SCANDINAV.CHEMOTECH CL.B has not paid dividends in the last 4 fiscal years.
Who owns SCANDINAV.CHEMOTECH CL.B
- Insiders 35.29%
- Institutions 15.40%
- Public & others 49.31%
- Shares outstanding 23.8M
- Free float 13.1M
SCANDINAV.CHEMOTECH CL.B company profile
- Company name
- SCANDINAV.CHEMOTECH CL.B
- Ticker
- 8V6.F
- ISIN
- SE0009242654
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- Medicon Village, Lund, Sweden, 223 63
- Phone
- 46 1 02 18 93 00
- Website
- chemotech.se
About SCANDINAV.CHEMOTECH CL.B
Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTech AB (publ) and changed its name to Neem's Hill AB in July 2026. The company was incorporated in 2013 and is headquartered in Lund, Sweden.
SCANDINAV.CHEMOTECH CL.B management
2- Mr. Stefan Mohan FrickFounder, CEO, President & Director · born 1974
- Ann OhlssonHead of Finance · born 1966